Business News • PR NewsWire • Abiraterone Acetate Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Naïve Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Survival

Abiraterone Acetate Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Naïve Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Survival

Abiraterone Acetate Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Naïve Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Survival

CHICAGO and RARITAN, N.J., June 3, 2017 /PRNewswire/ -- Janssen Research & Development, LLC today announced data from the pivotal phase 3 LATITUDE clinical trial, which showed ZYTIGA® (abiraterone acetate) plus prednisone, in combination with androgen deprivation therapy (ADT),...

View More : http://www.prnewswire.com/news-releases/abiraterone-acetate-provided-significant-clinical-benefit-in-patients-with-high-...

Releted News by prnewswire

Boston Biomedical Presents Data Suggesting Anti-Cancer Activity of Investigational Stemness Inhibitor Napabucasin in Seven Tumor Types at ASCO 2017

National Geographic Marks World Oceans Day With Activities Focused on the Importance of Protecting the World's Oceans

U.S. Census Bureau Daily Feature for June 4: Patently Precocious

Honda Sweeps Opening Race in Detroit